(Q46852643)

25 December 2017

meta-analysis

0 references

title

Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials? (English)

1 reference

25 December 2017

0 references

1

1 reference

25 December 2017

Gianluigi Mancardi

series ordinal

3

1 reference

25 December 2017

author name string

L Roccatagliata

series ordinal

2

1 reference

25 December 2017

M P Sormani

series ordinal

4

1 reference

25 December 2017

publication date

1 July 2009

1 reference

25 December 2017

Multiple Sclerosis Journal

published in

1 reference

25 December 2017

volume

15

1 reference

25 December 2017

issue

9

1 reference

25 December 2017

page(s)

1043-1047

1 reference

25 December 2017

Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106610

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106610

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106610

Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106610

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106610

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106610

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106610

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106610

Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106610

Subtraction MR images in a multiple sclerosis multicenter clinical trial setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106610

Nephrogenic system fibrosis: a radiologist's practical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106610

Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106610

Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509106610

21 January 2018

Identifiers

DOI

10.1177/1352458509106610

1 reference

25 December 2017

PubMed ID

19570818

1 reference

25 December 2017